BLUE

bluebird bio, Inc. [BLUE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BLUE Stock Summary

Top 10 Correlated ETFs

BLUE


Top 10 Correlated Stocks

BLUE


In the News

08:06 29 Sep 2023 BLUE

Are Gene Therapy Stocks The Market's Next Big Winners?

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

07:21 29 Sep 2023 BLUE

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.

05:14 29 Sep 2023 BLUE

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebird bio stock imply a gain of 99% over the next 12 months.

05:25 29 Sep 2023 BLUE

Is Bluebird Bio a Bargain Buy in September?

Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launching a new medicine.

06:05 29 Sep 2023 BLUE

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative after the longest positive signal since March 2021 on the weekly gauges. Last week three of the four picks gained over the 10% mark, closing up an average of +9.17% for the week with strong Segment 6 momentum.

10:15 29 Sep 2023 BLUE

1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street

Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another approval by the end of the year.

09:37 29 Sep 2023 BLUE

7 Very Oversold Nasdaq Stocks to Buy Right Now

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese economy.

02:47 29 Sep 2023 BLUE

bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.

12:57 29 Sep 2023 BLUE

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

09:55 29 Sep 2023 BLUE

Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates

Bluebird Bio (BLUE) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.29 per share a year ago.

BLUE Financial details

Company Rating
Buy
Market Cap
325.14M
Income
-83.15M
Revenue
9.4M
Book val./share
2.66
Cash/share
2.26
Dividend
-
Dividend %
-
Employees
323
Optionable
No
Shortable
Yes
Earnings
06 Nov 2023
P/E
-3.95
Forward P/E
-
PEG
0.44
P/S
34.35
P/B
1.14
P/C
1.34
P/FCF
-1.07
Quick Ratio
1.93
Current Ratio
2.13
Debt / Equity
1.06
LT Debt / Equity
0.83
-
-
EPS (TTM)
-0.9
EPS next Y
-
EPS next Q
-1.76
EPS this Y
-58.46%
EPS next Y
-
EPS next 5Y
705.56%
EPS last 5Y
-20.51%
Revenue last 5Y
-41.95%
Revenue Q/Q
189.37%
EPS Q/Q
-303.03%
-
-
-
-
SMA20
-14.79%
SMA50
-8.8%
SMA100
-24.88%
Inst Own
90.94%
Inst Trans
0.97%
ROA
-13%
ROE
-33%
ROC
-0.26%
Gross Margin
-38%
Oper. Margin
-1466%
Profit Margin
-884%
Payout
-
Shs Outstand
106.95M
Shs Float
91.4M
-
-
-
-
Target Price
14.13
52W Range
2.78-8.58
52W High
-62.25%
52W Low
+51%
RSI
34.89
Rel Volume
0.51
Avg Volume
4.2M
Volume
2.13M
Perf Week
-5.92%
Perf Month
-15.41%
Perf Quarter
-2.58%
Perf Half Y
-30.09%
-
-
-
-
Beta
0.92946
-
-
Volatility
0.06%, 0.27%
Prev Close
-1.31%
Price
3.02
Change
-1.95%

BLUE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
1.050.814.030.050.05
Net income per share
-10.68-14.31-9.95-8.16-3.39
Operating cash flow per share
-7.95-10.23-7.56-9.22-4.49
Free cash flow per share
-9.02-11.61-8.03-9.56-4.66
Cash per share
26.6220.0518.524.352.29
Book value per share
36.2323.2821.795.432.5
Tangible book value per share
35.7222.7921.425.352.36
Share holders equity per share
36.2323.2821.795.432.5
Interest debt per share
3.264.093.11.33.32
Market cap
3.34B3.14B1.74B688.41M543.81M
Enterprise value
3.1B3B1.62B616.83M712.19M
P/E ratio
-6.02-3.97-2.82-1.22-2.04
Price to sales ratio
61.2570.216.95187.99151.18
POCF ratio
-8.09-5.56-3.7-1.08-1.54
PFCF ratio
-7.13-4.9-3.49-1.05-1.49
P/B Ratio
1.772.441.291.842.77
PTB ratio
1.772.441.291.842.77
EV to sales
56.7167.166.45168.44198
Enterprise value over EBITDA
-5.47-3.71-2.54-1.14-2.57
EV to operating cash flow
-7.49-5.32-3.44-0.97-2.02
EV to free cash flow
-6.6-4.68-3.24-0.94-1.95
Earnings yield
-0.17-0.25-0.36-0.82-0.49
Free cash flow yield
-0.14-0.2-0.29-0.96-0.67
Debt to equity
0.080.150.140.241.43
Debt to assets
0.070.110.110.150.51
Net debt to EBITDA
0.440.170.20.13-0.61
Current ratio
9.695.155.972.21.56
Interest coverage
-39.12-23.360013.92
Income quality
0.740.710.760.781.32
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.190000
Research and developement to revenue
8.2213.042.3487.3766.93
Intangibles to total assets
0.010.020.010.010.02
Capex to operating cash flow
0.130.140.060.040.04
Capex to revenue
-1.02-1.71-0.12-6.28-3.67
Capex to depreciation
-3.25-4.37-1.5-1.17-2.64
Stock based compensation to revenue
2.033.60.6234.939.78
Graham number
93.386.5769.8531.5913.81
ROIC
-0.26-0.49-0.36-1.07-0.38
Return on tangible assets
-0.25-0.46-0.35-0.96-0.49
Graham Net
15.0910.910.780.5-2.17
Working capital
1.27B928.59M1.01B183.53M71.25M
Tangible asset value
1.86B1.26B1.33B368.63M185.83M
Net current asset value
1.06B709.74M789.34M117M-159.07M
Invested capital
0.080.150.140.241.43
Average receivables
8.52M13.38M19.82M19.1M11.09M
Average payables
15.35M30.41M32.3M23.74M25.49M
Average inventory
-258.81M-325.23M-147.02M-129.1M-54.96M
Days sales outstanding
93.16104.7939.031.14K1.09K
Days payables outstanding
7.35K5.27K1.46K243.13908.86
Days of inventory on hand
-208.74K-17.69K-10.13K-1.02K-51.22
Receivables turnover
3.923.489.350.320.33
Payables turnover
0.050.070.251.50.4
Inventory turnover
0-0.02-0.04-0.36-7.13
ROE
-0.29-0.61-0.46-1.5-1.36
Capex per share
-1.07-1.38-0.47-0.33-0.17

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.02000.020.06
Net income per share
-1.26-0.940.380.33-0.67
Operating cash flow per share
-1.28-0.94-0.66-0.84-0.67
Free cash flow per share
-1.36-0.96-0.72-0.85-0.68
Cash per share
1.81.712.123.092.26
Book value per share
2.441.952.33.452.66
Tangible book value per share
2.391.882.183.342.56
Share holders equity per share
2.441.952.33.452.66
Interest debt per share
3.973.423.31.742.82
Market cap
305.4M516.17M589.46M327.29M357.57M
Enterprise value
516.86M727.9M757.84M361.62M491.56M
P/E ratio
-0.82-1.694.572.4-1.23
Price to sales ratio
201.057.27K9.51K137.4651.9
POCF ratio
-3.24-6.7-10.47-3.78-4.92
PFCF ratio
-3.04-6.59-9.6-3.73-4.87
P/B Ratio
1.73.2530.921.24
PTB ratio
1.73.2530.921.24
EV to sales
340.2710.25K12.22K151.8871.34
Enterprise value over EBITDA
-5.57-8.2529.8-4.28-5.83
EV to operating cash flow
-5.48-9.45-13.47-4.17-6.76
EV to free cash flow
-5.15-9.3-12.35-4.12-6.69
Earnings yield
-0.3-0.150.050.1-0.2
Free cash flow yield
-0.33-0.15-0.1-0.27-0.21
Debt to equity
1.631.751.430.771.06
Debt to assets
0.510.530.510.390.46
Net debt to EBITDA
-2.28-2.46.62-0.41-1.59
Current ratio
1.121.271.563.032.13
Interest coverage
-617.24-225.8-2.06K-0.090
Income quality
0.941.01-1.75-4.081
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
42.03748.58740.3119.386.14
Intangibles to total assets
0.010.010.020.020.02
Capex to operating cash flow
0.060.020.090.010.01
Capex to revenue
-3.94-17.8-82.39-0.46-0.1
Capex to depreciation
-4.45-0.91-4.07-1.02-0.73
Stock based compensation to revenue
5.86129.7375.472.260.84
Graham number
8.326.414.435.066.34
ROIC
-0.13-0.120.030.02-0.09
Return on tangible assets
-0.16-0.150.060.05-0.11
Graham Net
-3.33-2.56-2.01-0.06-1.02
Working capital
18.6M33.71M71.25M235.14M152.96M
Tangible asset value
174.47M153.21M185.83M343.48M277.88M
Net current asset value
-226.02M-200.8M-159.07M13.08M-86.4M
Invested capital
1.631.751.430.771.06
Average receivables
11M11.51M11.66M13.16M15.49M
Average payables
26.61M21.74M21.86M22.16M15.06M
Average inventory
7.54M11.3M3.05M1.2M8.73M
Days sales outstanding
620.715.89K15.66K587.36201.62
Days payables outstanding
1.28K0102.65K512.78102.52
Days of inventory on hand
777.970-5.78K101.54128.38
Receivables turnover
0.140.010.010.150.45
Payables turnover
0.07000.180.88
Inventory turnover
0.120-0.020.890.7
ROE
-0.52-0.480.160.1-0.25
Capex per share
-0.08-0.02-0.06-0.01-0.01

BLUE Frequently Asked Questions

What is bluebird bio, Inc. stock symbol ?

bluebird bio, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol BLUE

Is bluebird bio, Inc. buy or a sell ?

8 stock analysts have 8 predictions with a medium analyst target price of $14.13. The lowest prediction is $5 and the highest is $25

What is BLUE stock prediction ?

What is bluebird bio, Inc. stock quote today ?

bluebird bio, Inc. stock price is $3.02 today.

Is bluebird bio, Inc. stock public?

Yes, bluebird bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap